Related Experiment Video

Updated: Aug 11, 2026

In vitro Functional Characterization of Mouse Colorectal Afferent Endings
14:09

In vitro Functional Characterization of Mouse Colorectal Afferent Endings

Published on: January 21, 2015

The recognition and treatment of the irritable bowel syndrome

R Sewell, R Smallwood

    Australian Family Physician
    |July 1, 1978
    PubMed

    More Related Videos

    Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform10:37

    Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

    Published on: November 30, 2016

    Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis06:19

    Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

    Published on: May 16, 2025

    Related Concept Videos

    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
    Drugs for Treatment of Constipation-Predominant IBS01:21

    Drugs for Treatment of Constipation-Predominant IBS

    Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
    Irritable Bowel Syndrome I: Introduction01:17

    Irritable Bowel Syndrome I: Introduction

    Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
    IBS is a chronic condition that can persist over a long period or recur frequently.
    The pathogenesis of IBS involves a complex interplay of the following factors:
    Altered...
    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
    Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
    Irritable Bowel Syndrome III: Medical and Nursing Management01:30

    Irritable Bowel Syndrome III: Medical and Nursing Management

    Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
    Irritable Bowel Syndrome01:23

    Irritable Bowel Syndrome

    DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...